Evonik's Strategic Pivot: Dividend Cut and Price Hikes Signal a Painful Transition

Evonik slashes dividend, hikes prices for key product, and cuts 2,000 jobs to counter weak sales and meet 2025 targets, signaling a painful shift in financial policy.

While the specialty chemicals group Evonik met its operational targets for 2025, shareholders are facing a period of significant austerity. The company's management is implementing an immediate global price increase for a key product, slashing its dividend, and abandoning its previous payout guarantee. This decisive shift in financial policy raises a critical question: are these painful measures the key to finally completing the conglomerate's protracted restructuring?

Financial Results Mask Underlying Strain

A superficial glance at the finalized figures for the past year presents a picture of resilience. The company reported an adjusted operating profit (EBITDA) of €1.87 billion, landing precisely within its forecast range. Net income also showed improvement, climbing to €265 million from €222 million. However, this performance comes at a cost to investor returns, marking a clear departure from the firm's previous commitment to consistent shareholder remuneration.

For 2025, the board has proposed a reduced dividend of €1.00 per share, down from €1.17 paid out for the prior year. Furthermore, starting in 2026, the payout policy will shift dramatically. The company plans to distribute only 40% to 60% of its adjusted net income annually, a move designed to bolster its financial flexibility during a challenging phase.

Immediate Actions to Counter Market Headwinds

These adjustments are a direct response to a difficult operating environment. In 2025, Evonik's total revenue contracted by 7% to €14.1 billion. A crucial profitability metric, the return on capital employed (ROCE), fell to 6.1%, leaving management far adrift from its medium-term target of 11%.

To counter these pressures, Evonik is enacting a two-pronged strategy. First, it has initiated an immediate worldwide price hike of 10% for its core product MetAMINO, a major revenue driver in animal nutrition. Concurrently, a sweeping cost-saving program is entering its final stage. The initiative, which will eliminate up to 2,000 positions—1,500 of them in Germany—is projected to yield annual savings of approximately €400 million beginning this year.

Market Sentiment Remains Cautious Amid Weak Guidance

The combination of this deep restructuring and persistent market weakness has left a pronounced mark on the company's valuation. Evonik shares closed the most recent trading session at €13.96, representing a decline of over 34% across a twelve-month horizon. The stock's current position, 7.6% below its 200-day moving average, underscores a sustained downward trend. Although a 14-day Relative Strength Index (RSI) reading of a deeply oversold 15.8 might typically suggest a potential rebound, a subdued outlook for 2026 is tempering optimism.

While the EBITDA target range for the coming year remains stable at €1.7 to €2.0 billion, management was forced to revise its sales expectation downward to a band of €13.5 to €14.5 billion. The business continues to be burdened by elevated energy costs, a sluggish economic climate, and global overcapacity in the sector.

The efficacy of this structural realignment and the immediate price increases will soon be measurable. The next reliable indicators for an operational turnaround will be provided with the release of quarterly figures on May 8. Shortly thereafter, on June 3, shareholders at the Annual General Meeting will be asked to formally approve the new, more restrictive dividend policy.